vs

Side-by-side financial comparison of HA Sustainable Infrastructure Capital, Inc. (HASI) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $114.8M, roughly 1.8× HA Sustainable Infrastructure Capital, Inc.). HA Sustainable Infrastructure Capital, Inc. runs the higher net margin — -46.8% vs -62.0%, a 15.2% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 13.3%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 4.2%).

HA Sustainable Infrastructure Capital, Inc. (HASI) is a specialized investment firm focused on sustainable infrastructure assets covering renewable energy, energy efficiency, sustainable real estate and low-carbon utility segments. It primarily operates in North American markets, providing long-term capital to eligible sustainable projects and delivering stable risk-adjusted returns to investors through recurring cash flows from operational underlying assets.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

HASI vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.8× larger
RARE
$207.3M
$114.8M
HASI
Growing faster (revenue YoY)
RARE
RARE
+12.6% gap
RARE
25.9%
13.3%
HASI
Higher net margin
HASI
HASI
15.2% more per $
HASI
-46.8%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
4.2%
HASI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HASI
HASI
RARE
RARE
Revenue
$114.8M
$207.3M
Net Profit
$-53.8M
$-128.6M
Gross Margin
Operating Margin
-57.4%
-54.7%
Net Margin
-46.8%
-62.0%
Revenue YoY
13.3%
25.9%
Net Profit YoY
-176.7%
3.5%
EPS (diluted)
$-0.38
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HASI
HASI
RARE
RARE
Q4 25
$114.8M
$207.3M
Q3 25
$103.1M
$159.9M
Q2 25
$85.7M
$166.5M
Q1 25
$96.9M
$139.3M
Q4 24
$101.3M
$164.6M
Q3 24
$82.0M
$139.5M
Q2 24
$94.5M
$147.0M
Q1 24
$105.8M
$108.8M
Net Profit
HASI
HASI
RARE
RARE
Q4 25
$-53.8M
$-128.6M
Q3 25
$83.3M
$-180.4M
Q2 25
$98.4M
$-115.0M
Q1 25
$56.6M
$-151.1M
Q4 24
$70.1M
$-133.2M
Q3 24
$-19.6M
$-133.5M
Q2 24
$26.5M
$-131.6M
Q1 24
$123.0M
$-170.7M
Operating Margin
HASI
HASI
RARE
RARE
Q4 25
-57.4%
-54.7%
Q3 25
-106.9%
Q2 25
-64.8%
Q1 25
84.7%
-102.6%
Q4 24
90.9%
-74.3%
Q3 24
-32.1%
-94.6%
Q2 24
39.5%
-79.1%
Q1 24
-151.9%
Net Margin
HASI
HASI
RARE
RARE
Q4 25
-46.8%
-62.0%
Q3 25
80.8%
-112.8%
Q2 25
114.9%
-69.0%
Q1 25
58.4%
-108.5%
Q4 24
69.2%
-80.9%
Q3 24
-23.9%
-95.7%
Q2 24
28.1%
-89.5%
Q1 24
116.3%
-156.8%
EPS (diluted)
HASI
HASI
RARE
RARE
Q4 25
$-0.38
$-1.28
Q3 25
$0.61
$-1.81
Q2 25
$0.74
$-1.17
Q1 25
$0.44
$-1.57
Q4 24
$0.58
$-1.34
Q3 24
$-0.17
$-1.40
Q2 24
$0.23
$-1.52
Q1 24
$0.98
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HASI
HASI
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$110.2M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.7B
$-80.0M
Total Assets
$8.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HASI
HASI
RARE
RARE
Q4 25
$110.2M
$421.0M
Q3 25
$301.8M
$202.5M
Q2 25
$86.5M
$176.3M
Q1 25
$67.4M
$127.1M
Q4 24
$129.8M
$174.0M
Q3 24
$44.1M
$150.6M
Q2 24
$145.7M
$480.7M
Q1 24
$61.4M
$112.3M
Stockholders' Equity
HASI
HASI
RARE
RARE
Q4 25
$2.7B
$-80.0M
Q3 25
$2.7B
$9.2M
Q2 25
$2.6B
$151.3M
Q1 25
$2.5B
$144.2M
Q4 24
$2.4B
$255.0M
Q3 24
$2.3B
$346.8M
Q2 24
$2.3B
$432.4M
Q1 24
$2.3B
$140.3M
Total Assets
HASI
HASI
RARE
RARE
Q4 25
$8.2B
$1.5B
Q3 25
$8.2B
$1.2B
Q2 25
$7.6B
$1.3B
Q1 25
$7.5B
$1.3B
Q4 24
$7.1B
$1.5B
Q3 24
$6.7B
$1.5B
Q2 24
$6.7B
$1.6B
Q1 24
$6.7B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HASI
HASI
RARE
RARE
Operating Cash FlowLast quarter
$167.3M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HASI
HASI
RARE
RARE
Q4 25
$167.3M
$-99.8M
Q3 25
$-121.8M
$-91.4M
Q2 25
$79.6M
$-108.3M
Q1 25
$-37.1M
$-166.5M
Q4 24
$5.9M
$-79.3M
Q3 24
$21.9M
$-67.0M
Q2 24
$-24.8M
$-77.0M
Q1 24
$20.9M
$-190.7M
Free Cash Flow
HASI
HASI
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
HASI
HASI
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
HASI
HASI
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
HASI
HASI
RARE
RARE
Q4 25
Q3 25
-1.46×
Q2 25
0.81×
Q1 25
-0.66×
Q4 24
0.08×
Q3 24
Q2 24
-0.94×
Q1 24
0.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HASI
HASI

Segment breakdown not available.

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons